#	Pagina
attuale pagina	/open-h2020/projects/197383/index.html
-1	/open-h2020/projects/215305/index.html
-2	/open-consip/fornitori/2021/profilo-08831790012/index.html
-3	/open-h2020/projects/221505/index.html
-4	/open-h2020/projects/211483/index.html
-5	/open-h2020/per-topic/saob/list/index.html
-6	/open-h2020/per-topic/chalcedonian/list/index.html
-7	/open-h2020/per-topic/khs/list/index.html
-8	/open-h2020/per-topic/vor/list/index.html
-9	/open-h2020/projects/210700/results.html
-10	/open-h2020/projects/195831/index.html

Opendata, web and dolomites

ADiRaS

Alzheimer’s Disease Diagnosis by Spectroscopy. Accurate and Non-Invasive Medical Device for the Diagnosis of Early Stage Alzheimer's Disease.

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

ADiRaS project word cloud

Explore the words cloud of the ADiRaS project. It provides you a very rough idea of what is the project "ADiRaS" about.

time disease alzheimer life treatment relatively puncture selling medical diagnosis procedure expensive saving fluid total people patient scans bleeding company institutionalization price emission solution canal healthcare delaying suffer performing ht diagnostic temporary consists received pain reactions patients numbness severe ad 1500 rs 65 expert accurate spinal nursery onto tomography admission affordable device infections 400 invasive techniques cerebrospinal reference proper marker population legs screening symptoms living analyzes lumbar earlier revolutionary radioactive brain huge raman absolutely pet quality multiple 8bn allergic positron 2050 million improves plasma diagnose injected 50 ameliorating headaches net market first blood lacks aging spectroscopy

Project "ADiRaS" data sheet

The following table provides information about the project.

Coordinator	RAMAN HEALTH TECHNOLOGIES SL Organization address address: AVDA FRANCISCO VALLES 8 BIOINCUBADORA PARQUE TECNOLOGICO city: BOECILLO VALLADOLID postcode: 47151 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2015
Funding Scheme	SME-1
Starting year	2015
Duration (year-month-day)	from 2015-07-01 to 2015-10-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	RAMAN HEALTH TECHNOLOGIES SL RAMAN HEALTH TECHNOLOGIES SL Organization address address: AVDA FRANCISCO VALLES 8 BIOINCUBADORA PARQUE TECNOLOGICO city: BOECILLO VALLADOLID postcode: 47151 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BOECILLO VALLADOLID)	coordinator	50˙000.00

Map

Project objective

Raman HT is a company expert on Raman Spectroscopy (RS) which has developed a revolutionary medical device to diagnose Alzheimer’s Disease (AD) in blood plasma for the first time. Currently, there are only two accurate methods to diagnose AD, expensive, invasive with multiple side effects. Positron Emission Tomography (PET) scans the patient’s brain after being injected with a radioactive marker (cost of €1500) which can cause major allergic reactions. The other method analyzes the cerebrospinal fluid, which requires performing the patient a lumbar puncture. This procedure (relatively expensive, €400) can cause severe headaches, temporary pain of numbness to legs, infections and bleeding into the spinal canal.

There are more than 30 million people living with AD in Europe and more than 7 million people that have not received a diagnostic due to the cost and side effects of the current techniques. Without diagnostic, patients lacks of a proper treatment that improves patients life quality ameliorating the symptoms of the disease. The earlier the diagnosis, the earlier the treatment delaying nursery admission.

Our solution consists of performing RS onto a sample of blood plasma. It is not invasive, has absolutely no side effects and an estimated selling price of €100. Our solution, making AD diagnosis more affordable, can produce net saving of €2,8bn to the European Healthcare system only delaying institutionalization. Our aim is to bring our solution into the market as a reference diagnostic method for screening patients for Alzheimer’s Disease. Alzheimer Disease is a huge problem that Europe needs to address due to the aging population. By 2050, 50% of the total European population will be over 65 years old and more importantly, 1 out 3 will suffer from Alzheimer’s Disease.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADIRAS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ADIRAS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination